Montai Health
Lamya Shihabuddin is a seasoned professional in drug discovery and development, currently serving as Chief Scientific Officer at Montai Therapeutics and 4:59 NewCo, a 5AM Ventures Company. Additionally, Lamya is a member of the Scientific Advisory Board at Coave Therapeutics and has held significant roles at Sanofi, including Head of Research for Genetic Neurologic Diseases and Neuroinflammation & Repair. Lamya's academic background includes a Doctor of Philosophy (PhD) in Neurobiology and Neurosciences from the University of Miami Miller School of Medicine and a Master of Science in Neuroscience from the American University of Beirut.
This person is not in any offices
Montai Health
Montai is harnessing nature's power through digital technology to treat and prevent chronic disease, hence improving health outcomes for as many people as possible. To address this crucial global concern, the business is pioneering cutting-edge technology to develop AnthromoleculeTM medications, which are derived from a privileged class ofcompounds with a history of safe human use. Our human-centered foundation can enable the rapid and repeatable development of safe, efficacious, and accessible medicines for as many diseases and people as possible by creating the world's first Anthromolecule Bioactivity Atlas, which comprehensively maps potent connections to all known biological pathways underlying disease.